Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

Twice-weekly carfilzomib is approved at 27 and 56 mg/m2 to treat relapsed multiple myeloma patients. In the phase III study ARROW, once-weekly 70 mg/m 2 carfilzomib prolonged the median progression-free survival of relapsed multiple myeloma patients in comparison with twice-weekly 27 mg/m2 carfilzom...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo, Tommaso Caravita Di Toritto, Francesco Di Raimondo, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro, Alessandra Larocca
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Ferrata Storti Foundation 2019-08-01
Saila:	Haematologica
Sarrera elektronikoa:	https://haematologica.org/article/view/9013
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!